9/12 5:30 pm - 8:30 pm
HBA presents 'Putting Academia-Industry Research Partnerships to Work.' Novartis, 1 Health Plaza, East Hanover, NJ more
9/24 4:00 pm - 6:00 pm
CURE presents healthcare investment banker Anthony Gibney of Leerink Swann. Yale Anlyan Center, 300 Cedar Street, New Haven more
10/1 4:00 pm - 6:00 pm
CURE/Yale BioHaven presents Trevi Therapeutics. Anlyan Center, 300 Cedar Street, New Haven. Watch for details.
10/8-9 12th annual BIO Investor Forum. The Palace Hotel, San Francisco more
10/15 6:00 pm - 9:30 pm
HBA presents Women's Healthcare Innovation and Leadership Showcase. Sanofi Campus, 55 Corporate Drive Auditorium, Bridgewater, NJ more
11/7 10:00 am - 3:00 pm
CT Innovation Summit. Mentor meetings, awards ceremony, and more. Co-sponsored by CURE. Oakdale Theater, Wallingford more
11/11-13 The BIO Convention in China. National Convention Center, Beijing more
12/3 5:45 pm - 7:30 pm
CURE Holiday Party. 'The best networking in town.' Café George, 300 George Street, New Haven. Save the Date!

Cost-saving discounts for CURE members!
CURE members can now receive discounts on various products and services, such as lab supplies, shipping services, and gases more


BioRelix, Inc.
5 Science Park at Yale
New Haven, CT 06511

Phone: 203-785-9282
Fax: 203-785-8058
Website: http://www.biorelix.com

Contact(s)
Brian R. Dixon, Ph.D. - President & CEO - bdixon@biorelix.com

General Information
Antibiotics have long been recognized as reliable drugs that have largely overcome the lethal and devastating causes of bacterial infections. All known classes of antibiotics are increasingly encountering widespread resistance by many prevalent bacterial pathogens that will continue to significantly affect human health in the coming decades. BioRelix is a drug discovery and development company focused on identifying new anti-infective drug treatments that will address these critical challenges in infectious disease treatment.

Research Activities
BioRelix is discovering and developing new treatments for infectious diseases that target RiboSwitches – an innovative class of RNA drug targets found in pathogenic bacteria and fungi. RiboSwitches are short stretches of messenger RNAs that bind small molecule metabolites and control genes that are essential for the survival of many disease-causing microbes. Several different classes of RiboSwitch RNAs have been identified and each potentially could serve as a novel anti-infective drug target. BioRelix owns a worldwide license to develop and market RiboSwitch targeted medicines and is building a portfolio of products.

Other Information
Ownership: Private
CT Employees: 12
World Employees: 12

Back